Next 10 |
home / stock / imvt / imvt articles
Composition of matter patent issued with coverage until June 2043 Patent also includes methods of use and methods of manufacturing claims NEW YO...
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. KMX reported a t...
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of ba...
U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 150 points on Thursday. Shares of Micron Technology, Inc...
Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results. Steelcase posted upbeat earnings for its...
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. Shares of FedEx Corporation (NYSE: F...
U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Thursday. Here are some big stocks recording gains in today’...
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal li...
Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an updated investor presentation with additiona...
News, Short Squeeze, Breakout and More Instantly...
Immunovant Inc. Company Name:
IMVT Stock Symbol:
NASDAQ Market:
2024-04-02 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Composition of matter patent issued with coverage until June 2043 Patent also includes methods of use and methods of manufacturing claims NEW YO...
Composition of matter patent issued with coverage until June 2043 Patent also includes methods of use and methods of manufacturing claims NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) , a clinical-stage immunology company dedicated to enabling no...